(77/93) of these animals, the level ofhuman enzyme was equal to or greater than the level of endogenous murine enzyme. Even in bone marrow transplant recipients reconstituted for over 1 year, significant levels of gene expression were observed for each of the vectors in their bone marrow, spleen, macrophages, and B and T lymphocytes. However, derivatives of the parental MFG-ADA vector which possess either a single base mutation (termed B2 mutation) or myeloproliferative sarcoma virus LTRs rather than the Moloney murine leukemia virus LTRs led to significantly improved gene expression in all lineages. These studies indicate that retroviral vectors which employ viral LTRs for the expression of inserted sequences make it possible to obtain high levels of a desired gene product in most hematopoietic cell lineages for close to the lifetime of bone marrow transplant recipients.
Despite considerable progress in efforts to develop effective genetic therapies for diseases involving hematopoietic cells, significant technical hurdles remain. First, while various transduction protocols have been developed to efficiently transfer genes into murine hematopoietic stem cells (1-7), it has not been possible to achieve efficient gene transfer into reconstituting cells of large animals (8, 9) . It is unclear to what extent this problem is vector related (e.g., insufficient titers, host range) or a consequence of a lack of knowledge regarding the optimal conditions for proliferation and/or efficient engraftment of appropriate target cells. A second important technical stumbling block relates to the development of retroviral vectors possessing the appropriate signals for high-level constitutive expression of inserted genes in hematopoietic cells in vivo. Although a number of groups have demonstrated the expression of genes in mice reconstituted with transduced bone marrow (BM) cells, others have experienced difficulties (10) (11) (12) . Overall, few general principles regarding features ofvector design important for gene expression in vivo have emerged. In particular, because of differences in vector backbones, inserted
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genes, viral titers, transduction protocols, and other experimental parameters, it has been impossible to directly compare the performance of different vectors and to determine the features of vector design which most critically affect gene expression in hematopoietic cells in vivo. In addition, few studies have examined the ability of transferred genes to be expressed for very long times (e.g., the lifetime of the transplant recipients), a clearly important goal of gene therapy for diseases involving hematopoietic cells.
We have addressed the above issues regarding gene expression in vivo through the construction of various retroviral vectors which encode the same gene product, human adenosine deaminase (hADA), and possess the same vector backbone yet differ specifically in transcriptional control sequences suggested by other studies to be important for vector gene expression. BM transplant (BMT) recipients engrafted by cells transduced by each vector were generated and the levels of vector expression were determined at both 5-7 months and >1 year after transplantation. An important conclusion from these studies is that simple vectors which employ viral long terminal repeats (LTRs) for the expression of inserted sequences make it possible to obtain high levels of a desired gene product in most hematopoietic lineages for close to the lifetime of a BMT recipient. Our results also suggest that the choice of viral transcriptional control sequences may be important for obtaining particularly high levels of gene expression.
MATERIALS AND METHODS
Recombinant Retroviruses and Virus-Producing Cells. Vectors were constructed by standard cloning procedures. The parental MFG-ADA vector consists of the following sequences inserted between the HindlIl and EcoRI sites of plasmid pBR322: (i) 396 bp of 5' murine chromosomal DNA (5' flanking sequence), (ii) an entire Moloney murine leukemia virus (Mo-MLV) 5' LTR and adjacent sequence up until the Nar I site at nt 1035 (a 6-bp Sma I linker was inserted at nt 624; see ref. 13 for numbering of Mo-MLV-derived sequences), (iii) a sequence containing the viral 3' splice acceptor and spanning nt 5401-5780 (the A nucleotide of the Nla III site has been changed to a C to create an Nco I site at the end of this fragment), (iv) hADA cDNA sequence extending from the ATG initiation codon at nt 74 to an Acc I site at nt 1324 (14) , (v) (1995) Ban II-Nhe I fragment of MFG-ADA which contains the hADA cDNA with a 6-kbp Ban II-Nhe I fragment of pC663neoR which contains the MPSV LTRs (15) . This method of construction yielded proviral sequences which possessed both 5' and 3' MPSV LTRs. Derivatives of MFG-ADA which carry the MPSV or Friend murine leukemia virus enhancer sequence were generated by replacing the Nhe I-Sac I and Nhe I-Kpn I segments of DNA in the 3' LTR of MFG-ADA with the corresponding sequences from the 3' MPSV LTR plasmid (kindly provided by P. Robbins, University of Pittsburgh) and the pFr-SV(X) plasmid (16) , respectively. Vectors that harbor the B2 mutation (17, 18 ) carry a single G-to-A mutation at position + 160 of the Mo-MLV sequence.
The aSGC-ADA vector contains the following sequences and is derived from pHSG (19) (19) .
Retrovirus-producing cell lines were generated by cotransfection of each retroviral plasmid with the plasmid pSV2-neo into the amphotropic packaging cell line 4,CRIP and selection for 10 days with G418 (1 mg/ml; GIBCO) (2, 22) . Cell-free supernatant was then harvested and used to infect 4,CRE cells (22) . An aSGC-ADA producer was isolated after direct transfection of 4CRE cells. Individual clones were screened for high-titer virus production by Southern blot analysis (2, 22, 23) . To verify the presence of the B2 mutation in the selected virus-producing cell lines and its transmission to infected NIH 3T3 cells, PCR primers corresponding to Mo-MuLV nt 72-92 and 470-490 were used to amplify a fragment of 400 bp which was then sequenced (finol DNA sequencing system; Promega).
Producer cell clones that transmitted the mutations to recipient cells at a frequency of 25-50% were chosen for use. Supernatants from virus-producing qCRE cells and plasma from transplant recipients were tested for the presence of replication-competent virus by the hisD mobilization assay (22) . Less than one virus particle per milliliter can be detected by this assay. All samples tested were found to be negative. DNA Analysis. Genomic DNA was prepared (24) and digested with Nhe I or EcI136II. Hybridization filters were probed with a 721-bp 32P-labeled BamHI-Bgl II fragment of the hADA cDNA (Multiprime DNA labeling system; Amersham). The copy numbers were determined on a phosphor imager (Fuji Bio-Imaging) relative to the intensity of bands corresponding to a single copy of the provirus. To account for uneven loading, the band signal was normalized to the endogenous murine ADA (mADA) band. Murine BM Transplantation and Analysis of Cell Populations. Infection and transplantation of BM from C57BL/6J mice were performed as described (2) . From 2.5 x 105 to 4.5 x 106 cells were injected per lethally irradiated (11 Gy) female host (2) . Selected animals were sacrificed 12-14 months after BM transplantation and samples of peripheral blood, BM, spleen, spleen-derived B and T lymphocytes, and BM-derived macrophages were prepared. In brief, B and T cells were harvested after 72 hr of stimulation with lipopolysaccharide (10,g/ml) and Con A (2,g/ml), respectively. More than 85% of cells were T or B lymphocytes as judged by flow cytofluorometry using anti-Thy-1.2 (PharMingen) or B220 (Caltag, South San Francisco, CA) antibodies. BM cells were cultured in medium containing 20% (vol/vol) L929-cell supernatant to generate macrophages. More than 95% of cells harvested after 10-11 days were macrophages by morphology.
ADA Enzyme Analysis. Isozyme-specific ADA activity was detected in cell lysates by nondenaturing isoelectric focusing (IEF) (2, 25) . Total protein concentration was determined for each sample with the Bio-Rad protein assay. Fixed amounts of total protein were loaded on the IEF gels (300 ,tg for peripheral blood cells; 150 ,ug for BM; 120 ,g for spleen, macrophages, and B lymphocytes; 75 ,ug forT lymphocytes). After 12 min of staining reaction, the gels were fLxed and the colorimetric intensity of each band was quantified with a computing densitometer (Molecular Dynamics). Since multiple gels were necessary to analyze all of the samples, a separate gel was run which included samples from each gel to provide a means of normalizing the data obtained from the individual gels.
RESULTS AND DISCUSSION
Generation of Recombinant Viruses Encoding hADA. The starting point for our studies of vector design was the construction of MFG-ADA (Mo-LTR construct) (Fig. 1A) . The MFG vector, constructed in our laboratory (L. Spain, P. Robbins, and R.C.M., unpublished data; see also refs. [26] [27] [28] , employs the Mo-MLV LTRs for transcription of the viral genome. Additionally, the vector retains both the 4, and 4'+ sequences necessary for efficient encapsidation of recombinant genomes into virus particles (29) (30) (31) Since the direct enzymatic assay of ADA activity in extracts does not provide a means of distinguishing human activity from the endogenous murine activity, we chose to employ a semiquantitative IEF enzyme assay (2, 25) . In this assay, hADA activity can be readily separated from mADA activity and the relative levels of the two activities can be estimated by densitometry measurements of labeled reaction products. We have shown, using dilutions of extracts that are within the range of protein loaded in the current studies and the time of incubation employed, that the enzyme activity assay generates signals proportional to the amount of enzyme activity and reflects the tissue-specific differences in ADA expression observed previously (2) (see also Fig. 3B ). Because a small portion (10-20%) of hADA migrates at the position of the murine enzyme, the assay does consistently underestimate the absolute amount of human activity and, therefore, the ratio of human to murine enzyme in extracts. In extracts containing In the next series of experiments, expression of the vectors in different hematopoietic cell types was examined through the fractionation of each cell population and subsequent quantitation of enzyme activity and proviral copy number. In light of the large number of experiments possible, we restricted this analysis to three to six animals engrafted with cells transduced by either MFG-ADA, MFG(B2)ADA, MFG(Fr-Enh)ADA, MFG(MPSV)ADA, or aSGC-ADA. The cell populations subjected to enzyme and DNA analysis included whole BM, whole spleen, fractionated macrophages, T lymphocytes, and B lymphocytes. The data may be summarized as follows.
(i) Proviral copy number achieved by different viruses. A significant proportion of the various hematopoietic cell populations carried proviral sequences even at >1 year after transplantation (Fig. 3A) (0.2-0.7 per cell) in all lineages, in spite of differences in viral titers. There was, however, significant variation in proviral copy number from mouse to mouse. In addition to differences in hematopoietic stem-cell transduction efficiencies that may be due to intrinsic characteristics of the virus-producing cell clones (e.g., production of growth factors, adhesiveness of monolayer), the previous demonstration of the ability of specific transduced stem-cell clones to contribute unequally to different cell lineages (38) may also explain the rather large variations in copy numbers observed.
(ii) Expression levels of hADA achieved by different viruses. Levels of ADA activity differ considerably among different populations of hematopoietic cells (Fig. 3B and (Fig. 3 C-H Fig. 3 B and H, all of the data in Fig. 3 are expressed in the same arbitrary units of enzyme activity and therefore can be directly compared.
The data illustrate several important points about vectormediated gene expression. First, while all vectors led to expression in all tissues examined, differences in the absolute levels of expression achieved by the different viruses were evident. However, because of the significant variation in expression levels from mouse to mouse, and the relatively small numbers of animals examined, we applied statistical analysis to the data. In Fig. 3 (Fig. 3F) . These results are particularly noteworthy in light of the probability that efficient ADA gene expression in T cells will be critical for successful implementation of gene therapy for ADA deficiency. Since, as pointed out earlier, the in situ gel assay leads to an underestimate of the levels of hADA activity, the actual hADA activity that can be achieved in T cells after stem-cell transduction is likely to be even higher than we report.
A last important finding is that, perhaps with the exception of the parental MFG-ADA vector, similar levels of hADA expression were observed from tissue to Nevertheless, the data suggest that those vectors offer improved expression and that the improvement appears to be general, in that it occurs in most cell lineages.
